Colestipol and Cholestyramine Resin

Authors:
  • CGCharles J. Glueck
    Charles J. Glueck
  • SFStarr Ford
    Starr Ford
  • DSDeborah Scheel
    Deborah Scheel
  • PSPaula Steiner
    Paula Steiner

Abstract
Two bile acid-sequestrant anion exchange resins, colestipol (U-26, 597A) and cholestyramine resin (Questran), were given in doses of 20 gm/day for four months each in a 14-month placebo crossover study to 25 patients with familial type II hyperlipoproteinemia. Plasma cholesterol and β-lipoprotein cholesterol were reduced to normal levels in 20 and 22 subjects, respectively, by one or both drugs. Coupled with low cholesterol, low saturated fat, polyunsaturate-rich diet, colestipol and cholestyramine provide parallel and alternative approaches to normalization of cholesterol and β-lipoprotein cholesterol in familial type II hyperlipoproteinemia.